Compare Repligen Corporation Common Stock (RGEN) vs Rigetti Computing Inc (RGTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Rigetti Computing Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Rigetti Computing Inc trades at $11.53 (market cap $4.27B). The key difference: Repligen Corporation Common Stock is far larger — about 2.6× Rigetti Computing Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Rigetti Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Rigetti Computing Inc for 36 Days on average.
| RGEN | RGTI | |
|---|---|---|
Market Cap | $11.14B | $4.27B |
Volume | 1,259,263 | 14,966,259 |
Sector | Health | Technology |
52-Week High | $194.57 | $56.34 |
52-Week Low | $102.87 | $11.68 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $11.02B | $3.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
RGTI trades at $12.78, down 3.55% today, with bearish technical signals but strong analyst support. The company shows negative profitability with a -1,787.4% net income margin despite recent earnings beats. Revenue growth from $7M to $13M (2025-2026) is overshadowed by escalating losses. Cash flow remains negative, though financing activities provide liquidity. Recent quantum computing sector news highlights competitive positioning and technological advancements.
Outlook remains speculative with high execution risk; Wall Street consensus is bullish (85.7% buy ratings) with a $21.67 price target implying 70% upside. Key risks include sustained losses, intense competition, and reliance on future quantum technology adoption. The stock offers high-risk growth potential for investors comfortable with speculative emerging technology plays.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Rigetti Computing Inc
Rigetti Computing, Inc. is a pioneer in quantum computing, focusing on developing and deploying quantum-classical computing systems. The company designs and fabricates superconducting quantum processors and integrates them with a full-stack software and control platform. Rigetti offers access to its quantum computers through the cloud, aiming to solve complex computational problems that are intractable for classical computers, with applications in finance, chemistry, and machine learning.
Read more on RGTI →
